Indacaterol

• UNSPSC Description:

  Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research[1][2].

• Target Antigen:

  Adrenergic Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cancer; Endocrinology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/indacaterol.html

• Solubility:

  DMSO : 62.5 mg/mL (ultrasonic)

• Smiles:

  OC1=CC=C([C@@H](O)CNC2CC(C=C(CC)C(CC)=C3)=C3C2)C4=C1NC(C=C4)=O

• Molecular Weight:

  392.49

• References & Citations:

  [1]Lee SU, et al. Indacaterol inhibits tumor cell invasiveness and MMP-9 expression by suppressing IKK/NF-κB activation. Mol Cells. 2014 Aug;37(8):585-91. |[2]Calzetta L, et al. Effects of the new ultra-long-acting β2-AR agonist indacaterol in chronic treatment alone or in combination with the β1-AR blocker metoprolol on cardiac remodelling. 2015. Drug Test Anal. 2020 Aug 27.|J Chromatogr A. 2024 Feb 22:1717:464696.|J Neuroimmunol. 2019 Jul 15;332:37-48.|Pharmaceutics. 2020 Feb 11;12(2):145.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  312753-06-3